摘要
表皮生长因子受体酪氨酸激酶抑制剂(EGFRTKI),如吉非替尼和厄洛替尼改善非小细胞肺癌(NSCLC)患者的生存。不幸的是,获得性耐药终会出现在大多数最初对治疗有反应的患者中。目前已知的针对获得性耐药的分子机制,可能仅解释约70%的临床病例。在这项研究中,使用非小细胞肺癌细胞模型H1650,我们构建了一个吉非替尼耐药细胞株h1650gr在增加剂量和长期药物暴露实验。RNA测序和全基因组SNP阵列进行调查的转录组和基因组改变可能参与了吉非替尼耐药性。通过比较h1650gr和H1650细胞之间的表达谱,我们确定了许多的差异表达基因,其中包括FOXM1(DEGS)。在PI3K/Akt通路,预测Akt活性将被抑制。然而,基因在吉非替尼诱导的细胞凋亡中扮演着重要的角色,包括TP53、FOXO3和BAD,且没有上调。信号网络分析(IPA)典型相关通路分析显示,在h1650gr细胞下p53信号被抑制,下调促凋亡基因Fas、PUMA、Noxa,上调抗凋亡基因BIRC5 /存活素 。此外,大量的免疫相关基因差异表达,其中吉非替尼耐药中的作用需要进一步调查。利用全基因组拷贝数变化(CNAS)同样进行了分析而且Noxa位于h1650gr独特的拷贝数损失区,18q21。我们的研究结果表明,在h1650gr中高表达的EGFR-TKI耐药可能是由多方面因素综合产生的。
关键词: CNAS,差异表达基因,耐药性,EGFR激酶抑制剂,肺癌,SNV,转录组。
Current Cancer Drug Targets
Title:An Integrative Analysis of the Putative Gefitinib-resistance Related Genes in a Lung Cancer Cell Line Model System
Volume: 15 Issue: 5
Author(s): Xiaohong Han, Manjiao Liu, Shuai Wang, Guanting Lv, Li Ma, Changqing Zeng and Yuankai Shi
Affiliation:
关键词: CNAS,差异表达基因,耐药性,EGFR激酶抑制剂,肺癌,SNV,转录组。
摘要: The epidermal growth factor receptor-tyrosine kinase inhibitors (EGFRTKI), such as gefitinib and erlotinib have improved the survival of patients with nonsmall cell lung cancer (NSCLC). Unfortunately, acquired resistance will eventually develop in most patients who initially respond to the therapy. Currently known molecular mechanisms for such an acquired resistance may interpret only about 70% of clinical cases. In this study, using NSCLC cell model H1650, we constructed a gefitinib resistant cell line H1650GR through long term drug exposure with increased doses. RNA sequencing and whole genome SNP array were applied to investigate the transcriptome and genome alterations possibly involved in gefitinib resistance. By comparing the expression profiles between H1650GR and H1650 cells, we identified a large set of differentially expressed genes (DEGs), including FOXM1. In the PI3K/AKT pathway, AKT activity was predicted to be inhibited. However, genes that play important roles in gefitinib-induced apoptosis, including TP53, FOXO3 and BAD, were not up-regulated. Ingenuity Pathway Analysis (IPA) canonical pathway analysis showed that p53 signaling was inhibited in H1650GR cells, with down-regulation of pro-apoptosis genes FAS, PUMA, NOXA, and upregulation of anti-apoptosis genes BIRC5/Survivin. Besides, a large number of immune response-related genes were differently expressed, the role of which in gefitinib resistance requires further investigation. Whole genome copy number alterations (CNAs) were also analyzed and NOXA was located in the H1650GR unique copy number loss region, 18q21. Our results suggested that the much higher EGFR-TKI resistance in H1650GR may be produced by the integration of multi-aspect factors.
Export Options
About this article
Cite this article as:
Xiaohong Han, Manjiao Liu, Shuai Wang, Guanting Lv, Li Ma, Changqing Zeng and Yuankai Shi , An Integrative Analysis of the Putative Gefitinib-resistance Related Genes in a Lung Cancer Cell Line Model System, Current Cancer Drug Targets 2015; 15 (5) . https://dx.doi.org/10.2174/1568009615666150416122422
DOI https://dx.doi.org/10.2174/1568009615666150416122422 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Photodynamic Therapy: The Development of New Photosensitisers
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in Antibody-Drug Conjugates for Breast Cancer Treatment
Current Medicinal Chemistry Patent Survey of Resveratrol, Taxol, Podophyllotoxin, Withanolides and Their Derivatives Used in Anticancer Therapy
Recent Patents on Biotechnology Radioprotective Effects of Plants from the Lamiaceae Family
Anti-Cancer Agents in Medicinal Chemistry Current Development of ROS-Modulating Agents as Novel Antitumor Therapy
Current Cancer Drug Targets Molecular Mechanisms of the Action of Myricetin in Cancer
Mini-Reviews in Medicinal Chemistry Editorial [Hot topic: Apoptosis in Carcinogenesis and Cancer Therapy (Guest Editors: George G. Chen and Paul B.S. Lai)]
Current Cancer Drug Targets Microfluidic Methods for Non-Viral Gene Delivery
Current Gene Therapy Clinical Experience with Antiangiogenic Therapy in Leukemia
Current Cancer Drug Targets Sulfur Containing Acridine Derivatives in Preclinical Studies with Cancer Cell Lines
Current Medicinal Chemistry NF-κ B and Rheumatic Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Subject Index To Volume 1
Reviews on Recent Clinical Trials Review: Recent Clinical Trials in Epigenetic Therapy
Reviews on Recent Clinical Trials 3D-QSAR and Docking Studies on 2-acyliminobenzimidazoles Derivatives as Potent ALK Inhibitors
Letters in Drug Design & Discovery New Platinum and Ruthenium Complexes - the Latest Class of Potential Chemotherapeutic Drugs - a Review of Recent Developments in the Field
Mini-Reviews in Medicinal Chemistry Omega-3 Polyunsaturated Fatty Acids and Cancer
Anti-Cancer Agents in Medicinal Chemistry ZNF424 Induces Apoptosis and Inhibits Proliferation in Lung Carcinoma Cells
Current Molecular Medicine Large-Scale Production Means for the Manufacturing of Lentiviral Vectors
Current Gene Therapy Potential Role of PKC Inhibitors in the Treatment of Hematological Malignancies
Current Pharmaceutical Design Biological Activity of Carotenoids: Its Implications in Cancer Risk and Prevention
Current Pharmaceutical Biotechnology